Skip to main content

Decision-making within cells and differentiation entity therapies

Objective

"Our ITN has both scientific and therapeutic targets. Research in Work Package 1 (WP1) aims to advance understanding of normal blood cell development and why primitive cells fail to differentiate in acute myeloid leukaemia (AML). Research in WP2 will use the information gained from WP1 to develop ways of alleviating the differentiation block in AML and so deliver new agents for use in differentiation therapy. This type of therapy aims, using only mildly toxic treatments, to induce terminal maturation of leukaemia cells and accelerate their death. WP2 responds to the urgent need to devise milder treatments, especially for older and frailer AML patients. Participants have already identified a number of promising new therapeutic agents. Working across these two complementary areas will train our Early Stage Researchers (ESR) to understand the translation of new fundamental science into the development of new therapies. The ITN brings together scientists who have made important advances in the fields of haematopoiesis and differentiation therapy, so will provide an excellent scientific training in these areas. Secondments/visits by ESRs to participants who run centres of expertise in leading edge technologies will provide training in these; and the time spent with private sector participants, and the courses they provide, will ensure that ESRs acquire the transferable skills they will need if they are to work well in, and build bridges between, commercial and publicly funded research organisations. ESRs will also receive management training. This research and training, which will develop our ESRs as versatile scientists, will involve the combined efforts of prestigious research institutes and universities, Poland’s leading governmental pharmaceutical R & D institute, two successful biopharmaceutical companies and a leading management consultancy."

Call for proposal

FP7-PEOPLE-2012-ITN
See other projects for this call

Coordinator

THE UNIVERSITY OF BIRMINGHAM
Address
Edgbaston
B15 2TT Birmingham
United Kingdom

See on map

Activity type
Higher or Secondary Education Establishments
Administrative Contact
May Chung (Ms.)
EU contribution
€ 753 274,50

Participants (7)

NATIONAL UNIVERSITY OF IRELAND GALWAY
Ireland
EU contribution
€ 550 419,30
Address
University Road
H91 Galway

See on map

Activity type
Higher or Secondary Education Establishments
Administrative Contact
Mari Vahey (Ms.)
UNIVERSITAT BASEL
Switzerland
EU contribution
€ 496 573,88
Address
Petersplatz 1
4051 Basel

See on map

Activity type
Higher or Secondary Education Establishments
Administrative Contact
Antonius Rolink (Prof.)
UNIWERSYTET WROCLAWSKI
Poland
EU contribution
€ 249 205,66
Address
Pl Uniwersytecki 1
50137 Wroclaw

See on map

Activity type
Higher or Secondary Education Establishments
Administrative Contact
Ewa Marcinkowska (Dr.)
ORBSEN THERAPEUTICS LIMITED
Ireland
EU contribution
€ 244 814,45
Address
Unit 1 Galway Business Park
H91 Galway

See on map

Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Stephen Elliman (Dr.)
THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL
United Kingdom
EU contribution
€ 285 056,62
Address
Old Brompton Road 123
SW7 3RP London

See on map

Activity type
Higher or Secondary Education Establishments
Administrative Contact
Yodry Vasquez (Mr.)
SIEC BADAWCZA LUKASIEWICZ - INSTYTUT FARMACEUTYCZNY
Poland
EU contribution
€ 448 620,90
Address
Ul. Rydygiera 8
01 793 Warszawa

See on map

Activity type
Other
Administrative Contact
Andrzej Kutner (Dr.)
CELENTYX LIMITED
United Kingdom
EU contribution
€ 285 056,62
Address
Vincent Drive 97
B15 2SQ Birmingham

See on map

Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Catherine Brady (Dr.)